Brigham and Women's Hospital

Funding Organization

Awards Grant

  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
  • A5272/A5280 Supplemental Funds from Adult Clinical Trials Group
  • A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"
  • A5361s: Pitvastatin to Reduce Physical Function Impairment and Frailty in HIV
  • AIDS Clinical Trial Group (ACTG 5324) -- A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV
  • AIDS Clinical Trials Group (ACTG) A5332/A5340 Salary Support
  • AIDS Clinical Trials Group Network (ACTG)
  • AIDS Clinical Trials Group: Protocol Funds
  • AIDS Clinical Trials Group: Protocol Funds FTE Funding
  • Aids Clinical Trial Group: ACTG
  • Aids Clinical Trials Group (ACTG) - TSG/Research Science Committee
  • Autophagy-Lysosome Pathway Function in HIV: Effects of Antiretroviral Therapy and Relevance to Neurocognitive Status
  • B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop De Novo Anti-HLA Alloantibodies will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection (CTOT-02/CCTPT-02)
  • Cardiovascular Disease Risk in HIV-Infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction Among REPRIEVE Trial Participants
  • Cardiovascular Inflammation Reduction Trial (CIRT)
  • Cardiovascular Inflammation Reduction Trial (CIRT): A Randomized Double-Blind Placebo-Controlled, Event-Driven Trial of Weekly Low-Dose Methotrexate (LDM) in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients
  • Computed Tomographic Characterization of Subjects Enrolled in the STATCOPE Investigation
  • Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)
  • ELEVATE-TIMI 56: Escalating Clopidogrel by Involving a Genetic Strategy
  • Effect of Low Dose Methotrexate on Endothelial Function and Inflammation in HIV - A5314
  • HPS 3/TIMI 55-Reveal (Randomized Evaluation of the Effects of Anacetrapib through Lipid-Modification)
  • HPS 3/TIMI 55: REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid-modification)
  • Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)
  • Kit Inhibition in Asthma (KIA)
  • Long Term Oxygen Treatment Trial (LOTT) Pharmacogenomics Ancillary Study
  • PEGASUS:A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction
  • PREPARE - Person Empowered Asthma Relief-fka Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations
  • Pharmacogenomics of Inhaled Corticosteroids to Reduce COPD Exacerbations
  • SAVOR: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus. A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial To Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stoke in Patients with Type 2 Diabetes
  • SOLID TIMI 52: Stabilization of Plaques Using Darapladib--A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events
  • Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus - SAVOR-TIMI53. A Multicentre, Randomised, Double-Blind, Placbeo-Controlled Phase IV Trial to Evaluate the Effects of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infraction or Ischaemic Stroke in Patients with Type 2 Diabetes
  • Treatments Against RA and Effect of FDG PET-CT: The TARGET Trial
  • Virology Speciality Laboratory